作者: Dariusz Dudek , Artur Dziewierz , Zbigniew Siudak , Tomasz Rakowski , Jaroslaw Zalewski
DOI: 10.1016/J.IJCARD.2008.10.020
关键词:
摘要: Abstract Background The majority of ST-segment elevation myocardial infarction (STEMI) patients are admitted to centers without primary percutaneous coronary intervention (PCI) facilities. Purpose the study was determine safety and outcomes in STEMI with transfer delay PCI>90 min receiving half-dose alteplase abciximab before PCI (facilitated reduced-dose fibrinolysis). Methods results Outcomes 669 ( 90 min who received full-dose were immediately transferred for compared effects 1311 P Conclusions This is first large report showing benefits transportation very long (>90 min) facilitated fibrinolysis patients. In fact, pharmacological treatment (combotherapy) effective overcoming deleterious time-delay on outcome, similar survival as short-time transportation, despite higher risk major bleeding complication.